Better survival for advanced bladder cancer with add-on treatment


By AGENCY

The use of an immunotherapy drug called durvalumab is a potential game-changer for patients with advanced bladder cancer. — dpa

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study.

Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of the cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two years after treatment.

Experts from the University of Sheffield (Sheffield) and Barts Cancer Institute at Queen Mary University of London (Barts) in Britain included 1,063 patients with operable bladder cancer in their study.

Patients were given either standard chemotherapy (cisplatin and gemcitabine) and surgery (530 people), or chemotherapy plus durvalumab before surgery and eight cycles of durvalumab after surgery (533).

The final stage phase 3 clinical trial found patients were 32% less likely to experience cancer recurrence or progression if they had immunotherapy, and were more likely to still be alive after two years.

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group.

Durvalumab is a treatment for non small cell lung cancer (NSCLC), but is also being trialled in other cancers.

Study co-lead investigator Dr James Catto, professor of urology at Sheffield and honorary consultant urological surgeon, said: “This is a major breakthrough in the treatment of bladder cancer.

“For many years, survival rates for advanced bladder cancer have remained stagnant, but our findings offer hope to thousands of patients who face this devastating diagnosis.

“Patients treated with durvalumab before and after surgery had both significantly higher survival rates and lower risks of the cancer returning, and didn’t face any additional serious side effects.

“This is important for patients undergoing chemotherapy and its numerous and often debilitating side effects.

“Our hope is that this treatment can be made available for NHS [UK National Health Service] patients as soon as possible following regulatory approval by the Medicines and Healthcare products Regulatory Agency, and that it becomes the new standard of care.

“Recent research suggests that cases of bladder cancer will increase by 50% over the next two decades, but yet, the level of awareness about bladder cancer in the UK remains low.”

ALSO READ: Bladder cancer 101

The trial was funded by British-Swedish biopharmaceutical company AstraZeneca, with the results published in the New England Journal of Medicine.

At the moment, around half of patients with muscle-invasive bladder cancer experience recurrence within three years.

Study principal investigator Dr Syed Hussain, professor and honorary consultant of medical oncology at Sheffield and Sheffield Hospitals NHS Foundation Trust, said the “magnitude of survival benefit seen will certainly be a game changer”.

He added: “These are exciting times in the management of muscle-invasive bladder cancer.

“We had not seen any additional survival benefit in previous trials investigating additional treatments in combination with standard-of-care cisplatin-based chemotherapy before surgery.

“By bringing these exciting new treatments earlier in the disease pathway, we will continue to see more patients being cured of muscle-invasive bladder cancer.”

Study lead author Dr Thomas Powles, professor of genitourinary oncology at Barts, said: “In (the) Niagara (trial), we showed for the first time that the addition of immunotherapy to chemotherapy increases the rate of overall survival.

“This is a major step forward for these patients.”

Ian Flower from Sheffield took part in the trial, which was run at Sheffield Teaching Hospitals NHS Foundation Trust, after being diagnosed with operable bladder cancer.

”I was happy to help with the trial, not just for myself, but in the hope that it could help other patients,” the 63-year-old said. – PA Media/dpa

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Bladder cancer , cancer , treatment , immunotherapy

Next In Health

Here's how you can develop pneumonia from getting the flu
Be social for your brain (and ward off dementia)
Tired of cow's milk? Why not try milk from a camel
From A to Zzzzs: The factors that affect our sleep
‘Yo-yo’ dieting increases risk of complications in diabetes
This childhood punishment actually energises the brain
Why we just can’t stop touching our faces
Being bilingual can help children with autism
When a loved one's heart attack affects your mental health
A lesser-known method of treating refractory GERD

Others Also Read